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Background: ADHD guidelines in the UK suggest that children and adults who respond to pharmacological
treatment should continue for as long as remains clinically effective, subject to regular review. To what extent
patients persist with treatment from childhood and adolescence into adulthood is not clear. This study aims to
describe, in UK primary care, the persistence of pharmacological treatment for patients with ADHD who started
treatment aged 6–17 years and to estimate the percentage of patients who continued treatment from childhood
and adolescence into adulthood.
Methods: The Health Improvement Network (THIN) database was used to identify patients with ADHD who
received their first prescription for methylphenidate/ dexamfetamine/atomoxetine, aged 6–17 years. Patients were
monitored until their ‘censored date’ (the earliest of the following dates: date the last prescription coded in the
database ended, end of the study period (31st December 2008), date at which they transferred out of their practice,
date of death, the last date the practice contributed data to the database). Persistence of treatment into adulthood
was estimated using Kaplan Meier analysis.
Results: 610 patients had follow-up data into adulthood. 213 patients (93.4% male) started treatment between
6–12 years; median treatment duration 5.9 years. 131 (61.5%) stopped before 18 years, 82 (38.5%) were still on
treatment age ≥18 years. 397 patients (86.4% male) started treatment between 13–17 years; median treatment
duration was 1.6 years. 227 (57.2%) stopped before 18 years, 170 (42.8%) were still on treatment age ≥18 years.
The number of females in both age categories was too small to formally test for differences between genders in
persistence of treatment.
Conclusion: Persistence of treatment into adulthood is lower (~40%) compared with published rates of
persistence of the condition (~65% when symptomatic definition of remission used). Due to the limited number
of patients with data past 18 years, it is important that ongoing monitoring of prescribing into later adulthood
is undertaken, particularly to observe the effects of recommendations in new guidelines.
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Attention deficit hyperactivity disorder (ADHD) was
once perceived as a condition of childhood only;
however increasing evidence has highlighted the exist-
ence of ADHD in adolescents and adults [1]. There is
now consensus amongst experts that ADHD, diagnosed
mainly using the broader Diagnostic and Statistical
Manual of Mental Disorders 4th Edition (DSM-IV)
criteria, may currently affect at least 1-2% of adults in
the United Kingdom (UK) and 2-4% worldwide [2-6].
The prevalence of ADHD in school-aged children and
adolescents in the UK using DSM-IV criteria is esti-
mated at 5% [7]. The prevalence of hyperkinetic disorder
(HKD) in school-aged children in the UK, characterised
by the persistent traits of severe and pervasive inatten-
tiveness, overactivity, and impulsiveness as defined by
the International Classification of Diseases 10th Revision
(ICD-10) criteria [8], is estimated at 1.5% [9].
Compared to children and adolescents, adults with
ADHD are more likely to exhibit inattentive symptoms,
as overt hyperactive symptoms tend to diminish with
age [10]. However, they continue to suffer from symp-
toms such as the inability to sustain attention over a
long period of time, disorganisation, forgetfulness and
poor time management skills. Adolescents and adults
with ADHD have higher rates of speeding offences and
involvement in road traffic accidents than controls
[10,11], are at an increased risk of substance use disor-
ders (alcohol and drugs) [12] and becoming involved in
crime and entering the criminal justice system [13].
Rates of separation and divorce have been reported to be
higher in adults with ADHD [10,11].
There are two populations of adults with ADHD; those
who are recognised and diagnosed by a health profes-
sional as having ADHD-associated impairments for the
first time in adulthood, of whom some may have been
previously misdiagnosed with other mental health condi-
tions, and those who had a diagnosis of ADHD in child-
hood with symptoms and impairments persisting into
later life. With regards to the latter cohort, studies con-
ducted in this area have reported various rates of persist-
ence of the disorder; a meta-analysis of follow-up studies
in patients with ADHD [14] found that persistence was
low (approximately 15% at age 25) when the syndro-
matic definition of remission was used (failing to meet
the full diagnostic criteria for ADHD or the maintenance
of full diagnostic status). However, the use of the symp-
tomatic definition of remission (fewer than the number
of symptoms required for a subthreshold diagnosis
(i.e. fewer than five symptoms, or 36% of symptoms) or
the maintenance of partial diagnostic status with impair-
ment) resulted in a persistence rate of approximately
65% [14,15]. Importantly, under current plans for revi-
sion of the DSM criteria, it is proposed that many of thesymptomatic remission cases will be re-classified as
meeting full diagnostic criteria due to the persistence of
four or more ADHD symptoms in either the inattentive
or hyperactive-impulsive domains, associated with con-
tinued impairment [16].
While ADHD symptoms may persist in the majority of
cases, many young people with ADHD make a good adjust-
ment during young adulthood and do not require ongoing
pharmacotherapy. In some cases however, long-term treat-
ment may be warranted due to the persistence of impairing
levels of ADHD symptoms. The National Institute for
Health and Clinical Excellence (NICE), in the UK, recom-
mend that if a child or adult responds adequately to treat-
ment, then drug treatment for ADHD should be continued
for as long as it remains clinically effective, with a review
conducted at least on an annual basis [1].
Currently, in the UK, only the stimulant Concerta XL W
(prolonged-release methylphenidate) and the non-stimulant
atomoxetine are indicated as continuation treatment in
adults who started their treatment with this medication in
childhood [17,18], however at the time the study was
conducted, atomoxetine was the only licensed product for
this indication.
Guidelines from North America [19], Europe [3] and
the UK [1,20] advocate that appropriate treatments
should be provided for adults with ADHD. Guidelines
from the UK in particular [1,20] are expected to have
significant effects on the prescribing of ADHD pharma-
cological treatments to adults in the UK; therefore an
up-to-date study to investigate treatment patterns in
adults with ADHD has been undertaken.
There are limited data on the treatment patterns of
ADHD during the transition from childhood to adulthood
in routine clinical practice. A recent longitudinal analysis
in the UK of a cohort of 44 patients aged 15 years in 1999
demonstrated that 20% of patients were still receiving
treatment at 18 years but none of the patients continued to
receive treatment for ADHD beyond the age of 21 years;
the research concluded that pharmacological treatment of
some patients might have been stopped prematurely [21].
However this study investigated patients aged 15–21 years
and only had data available up to December 2006 [21].
The Multimodal Treatment Study of Children with
ADHD (MTA) was a multisite study in the US designed to
evaluate the leading treatments for ADHD, including medi-
cation management, intensive behavioural treatment,
combination treatment or community care (which included
medication for approximately two-thirds of the sample).
The children were followed up and results of the MTA
study have been reported at 14, 24 and 36 months. At
14 months [22], the point at which randomisation ended,
the outcome strongly favoured medication (whether or not
in combination with behaviour therapy). Naturalistic
follow-up at 24 [23] and 36 months [24], reported that
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generally maintained, but differential treatment efficacy
was lost at and beyond 36-months [24].
The aim of the study is to estimate the persistence of
pharmacological treatment for ADHD into adulthood for
patients who started their treatment in childhood, or in
adolescence, and to estimate the percentage of children
and adolescents, stratified by gender, who continued long-
term treatment for ADHD into adulthood, in the UK
primary care setting.
Methods
Data source
A descriptive population-based cohort study was con-
ducted using data from The Health Improvement Network
(THIN). THIN contains anonymised computerised infor-
mation entered by general practitioners (GPs) in the UK.
With coverage of approximately 5.7% of the UK population
(2009), practices that use the database are broadly repre-
sentative of practices in the UK for patients’ characteristics
[25]. GPs participating in THIN are trained to record infor-
mation using the Vision software (In Practice Systems;
London, UK) and the validity of the database for research
has been supported by a number of studies [26-28]. Data
recorded in THIN include patient demographics e.g.
age, sex, details from GPs visits, diagnoses from special-
ist referrals and hospital admissions, and the results of
laboratory tests. Prescriptions issued by the GP are
directly generated from the computer. The Read Clin-
ical Classification is used to code specific diagnoses and
related signs and symptoms, and a drug dictionary
based on data from the Multilex classification is used to
code drugs. Prescriptions issued by specialists are not
coded directly in the database but information on some
of them may be available as free-text comments. Ethical
approval was granted by the Cambridgeshire 4 Research
Ethics Committee (ref: 09/H0305/81).
Data extraction
The procedure for patient identification has been described
previously in a study examining the prevalence and inci-
dence of ADHD drug prescribing in children and adults in
the UK [29]. In summary, patients were initially identified
according to whether they had a prescription record for
methylphenidate, dexamfetamine or atomoxetine (drugs
approved by Medicines and Healthcare products Regula-
tory Agency (MHRA) in the UK for the treatment of
ADHD) coded within the database between the study
period of January 1st 2003 and 31st December 2008. All
patients were required to have at least 12 months of
continuous registration in the database.
Patients who had a diagnosis of ADHD/HKD coded
within the database and had their first prescription for a
study drug coded between the age of 6 and 17 years wereidentified and were classified as receiving their first pre-
scription for a study drug either as a child (6–12 years) or
as an adolescent (13–17 years). Age of individuals on the
THIN database is calculated from the month and year of
birth up to the age of 15 years. Once individuals reach the
age of 15, age is calculated using the year of birth only
(i.e. 1st January of that year).
The ‘index date’ for each patient was the date of their first
prescription. [For some patients, this date preceded the
start of the study period January 1st 2003, however these
patients were eligible for inclusion if they remained on
treatment during the study period]. Data were analysed
from the index date to their ‘censored date’ which was the
earliest of (i) date the last prescription coded ended (ii) end
of the study period (31st December 2008) (iii) date at which
they transferred out of their practice if this occurred before
the end of the study period (iv) date of death (v) the last
date the practice contributed data to the database. The dur-
ation of treatment was calculated for each patient. As an
important aspect of this study was to determine persistence
of treatment into adulthood (≥age 18 years), only patients
who had continuous registration in the database up to and
including age 18 years were included.
The process used to identify these patients is pre-
sented in Figure 1.
Data analysis
The duration of each prescription was calculated using the
dose and quantity prescribed data. Based on previous work
conducted on ADHD within the UK setting [21], an inter-
val of more than 6 months between successive prescrip-
tions was classified as treatment cessation. In certain cases,
patients had more than one treatment episode i.e. patients
received a prescription for a study drug more than 6 months
after the end of the previous prescription. Patients with
multiple treatment episodes were excluded from the
current analyses as they were not considered persistent.
The overall duration of treatment, by gender, was calculated
from the start date of the first prescription to the calculated
end date (i.e. date prescription was issued plus the duration
of the prescription) of the last prescription coded in the
database. Data manipulation and analyses were conducted
using Stata/SE version 11.0 (StataCorp, College Station,
Texas, United States).
Outcomes
 To estimate the probability of continuing treatment
for patients who started treatment in childhood and
for those who started in adolescence, stratified by
gender, using Kaplan-Meier analysis.
 To estimate the percentage of children and adolescents
who persisted with ADHD pharmacological treatments
into adulthood (≥18 years).
Figure 1 Flow chart of the process used to identify study participants.
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Over the six year study period, a total of 3274 patients
between the age of 6 and 17 years met the criteria of ini-
tiating pharmacotherapy with one of the defined study
drugs and one treatment episode. Over 80% (2664) of
these patients did not have follow-up data beyond their
18th birthday; therefore they were not included in further
analyses. However, 610 patients (18.6%) did have follow-
up data in the database into adulthood (i.e. ≥18 years) and
thus were included in the persistency calculations; 213
(34.9%; 199 male, 93.4%) patients started treatment be-
tween the age of 6 and 12 years and 397 (65.1%; 343 male,
86.4%) patients started between 13 and 17 years old.
For the 610 patients who met the study inclusion cri-
teria, age at their ‘censored date’ [earliest of (i) date the last
prescription coded ended (ii) end of the study period (31st
December 2008) (iii) date at which they transferred out of
their practice if this occurred before the end of the study
period (iv) date of death (v) the last date the practice con-
tributed data to the database] was calculated (Table 1).Patients who started treatment aged between 6 and 12 years
Table 2 presents data on the duration of treatment for the
overall sample and stratified according to gender.A Kaplan-Meier analysis was performed on the 213
patients who started treatment aged between 6 and
12 years. These data are presented in Figure 2a and
stratified by gender in Figure 2b.
Of the 213 patients:
131 (61.5%) stopped treatment before age 18 years
(123 male, 8 female)
82 (38.5%) were still on treatment at age ≥18 years
(76 male, 6 female)
Of the 82 patients who were still on treatment at age
≥18 years, 15 patients (15 male; 18.3% of 82) subse-
quently stopped treatment within the study period. Thir-
teen of these patients stopped at age 18 years, one
patient stopped at age 20 years, and one at age 22 years.Patients who started treatment aged between 13 and 17
years
Table 3 presents data on the duration of treatment for
the overall sample and stratified according to gender.
A second Kaplan-Meier analysis was performed on
the 397 patients who started treatment aged between
13 and 17 years. These data for the overall sample are
Table 1 Age at ‘censored date’ for patients
‘Censored Age’
(Years)
Number of patients
6–12 years (n=213)
Number of patients
13–17 years (n=397)
18 89 146
19 56 100
20 41 69
21 20 43
22 4 23
23 3 8
24 - 4
25 - 1
26 - 1
27 - 1
28 - 1
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Figure 3b.
Of the 397 patients:
227 (57.2%) stopped treatment before age 18 years (202
male, 25 female)
170 (42.8%) were still on treatment at age ≥18 years
(141 male, 29 female)
Of the 170 patients, who were still on treatment at age
≥18 years, 45 (39 male, 6 female; 26.5% of 170) subse-
quently stopped treatment within the study period. Of
these 45 patients who subsequently stopped treatment;
30 patients (26 male) stopped aged 18 years, nine
patients (eight male) stopped at age 19 years, three
patients (two male) stopped aged 20 years, one patient
(male) stopped at aged 22 years, one patient (male)
stopped aged 23 years, and one patient (male) stopped
aged 24 years.
The records of the 358 patients who stopped treat-
ment (131 who started treatment aged 6–12 years; 227
who started treatment aged 13–17 years) prior to reach-
ing age 18 years were examined to ensure that these
patients remained under the care of the GP and hadn’t
left the practice. Of these 358 patients, 351 patients
(98%) received at least one prescription (for any treat-
ment) and/or had one medical record entered in theTable 2 Duration of treatment for patients who started
treatment between 6 and 12 years of age
Median
duration
Minimum
duration
Maximum
duration
Interquartile
range
Overall (n=213) 5.9 years 40 days 13.1 years 3.6 years
Males (n=199) 5.9 years 40 days 12.4 years 3.5 years
Females (n=14) 6.3 years 1.4 years 13.1 years 5.1 yearsdatabase after the calculated end date of their ADHD
drug treatment.
Discussion
It is well documented in follow-up studies as well as
from reports of epidemiological surveys that impair-
ments exist in people with ADHD that persist into
adulthood [5,30]. What is less well known is to what ex-
tent patients persist with pharmacological treatment
during the transition from childhood and adolescence
into adulthood.
Pharmacological treatment patterns in our study co-
hort were examined to determine how many patients
started treatment in childhood or adolescence and were
continuing to have prescriptions issued by their GP up
to and after turning 18 years. Two hundred and thirteen
patients who started treatment between the age of 6 and
12 years had reached 18 years or older within the study
period; of these 38.5% (82/213) were still receiving pre-
scriptions for a study drug at 18 years of age. Of these
82 patients, 15 patients subsequently stopped within
4 years of turning 18.
Patients who started treatment in adolescence were
also analysed to determine persistence into adulthood.
Of these 397 patients, 43% (170/397) were still pre-
scribed a study drug at age 18 years. Subsequently 45
patients stopped treatment aged ≥18 years.
It is recognised that once patients reach late adoles-
cence, many factors are involved in determining whether
a patient will remain on treatment. Some patients will
find they have an improvement in symptoms and no
longer require pharmacological treatment. Adolescents
may choose not to continue treatment and this increase
in self-autonomy has been reported in studies of adoles-
cents with chronic diseases [31]. Adolescents may also
decide to stop pharmacological treatment as there may be
less expectation from parents and teachers for continued
treatment as patients get older. Poor provision of treatment
services for older adolescents and young adults may also
contribute to the lower level of prescribing to these
patients. Typically in the UK, patients with ADHD are
under the care of child and adolescent mental health
services up to the age of 16 years or school-leaving
age with GPs responsible for prescribing ADHD med-
ications [32]. However, ADHD services within adult
mental health are currently poorly developed [33]
and clear arrangements for transition are often lack-
ing [34]. This can result in patients, in whom treat-
ment for ADHD is clinically warranted, not having
access to care by adult services for continuation of
overall management [35]. Furthermore, the restricted
licensing of the study drugs in adults may result in
GPs being unwilling to prescribe pharmacological
treatment in adulthood.
Table 3 Duration of treatment for patients who started
treatment between 13 and 17 years of age
Median
duration
Minimum
duration
Maximum
duration
Interquartile
range
Overall (n=397) 1.6 years 7 days 12.1 years 2.4 years
Males (n=343) 1.6 years 7 days 12.1 years 2.4 years
Females (n=54) 1.6 years 7 days 6.6 years 2.7 years
0.
00
0.
25
0.
50
0.
75
1.
00
213 151 15 0
Number at risk
0 5 10 15
Time from first prescription (years)
0.
00
0.
25
0.
50
0.
75
1.
00
14 8 1 0sex = Female
199 143 14 0sex = Male
Number at risk
0 5 10 15
Time from first prescription (years)
sex = Male sex = Female
a
b
Pr
ob
ab
ilit
y 
of
 c
on
tin
ui
ng
 tr
ea
tm
en
t
Pr
ob
ab
ilit
y 
of
 c
on
tin
ui
ng
 tr
ea
tm
en
t
Figure 2 a: Kaplan-Meier estimate of the probability of continuing pharmacological treatment for patients who started treatment
between 6 and 12 years (n=213). b: Kaplan-Meier estimate of the probability of continuing pharmacological treatment for male and female
patients who started treatment between 6 and 12 years (n=213).
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Higher ratios of males to females are observed in
ADHD in children; however in adulthood the ratio
appears to be equal [36]. The probability of persist-
ence in females who started drug therapy at a
younger age appeared to be lower than that of males,
however the trend was reversed in patients starting
in adolescence. Given the low number of female
patients, we were unable to make any inferences on
the differences observed between the genders.
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Figure 3 a: Kaplan-Meier estimate of the probability of continuing pharmacological treatment for patients who started treatment
between 13 and 17 years (n=397). b: Kaplan-Meier estimate of the probability of continuing pharmacological treatment for male and female
patients who started treatment between 13 and 17 years (n=397).
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[37] examined the long-term outcomes of ADHD. Over-
all, the results showed that the long-term outcomes of
ADHD when left untreated are poor compared with
non-ADHD controls, and that treatment of ADHD
improves long-term outcomes, but usually not to the
level observed in non-ADHD individuals. These data
reinforce the importance of treatment continuation for
patients with ADHD as they transition from childhood
and adolescence to adulthood.Strengths and limitations
A significant strength of the study was the use of a large
database such as THIN which provided primary care
data on a study cohort of over 4500 patients. THIN has
been used widely in epidemiological research, including
studies on mental health and in particular ADHD drug
prescribing [29,38,39]. The use of longitudinal data
allowed us to monitor the prescribing patterns to
patients as they transition from childhood/adolescence
to adulthood. However, the use of THIN primary care
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regions in the UK still depend on specialist services to
prescribe medications for ADHD in children, adoles-
cents or adults and these would not be systematically
represented in the data from the THIN database.
A limitation of this study was that only a low propor-
tion of patients reached 18 years within the study period
(9% for patients starting in childhood, 44% for patients
starting in adolescence). In addition, only 46 patients
(7 patients starting in childhood, 39 patients starting in
adolescence) had data in the database post 21 years of
age, which limited analysis of persistence further into
adulthood. The low number of patients also prevented
analyses of differences in persistence between male
and female patients. This is an area which warrants
further investigation in the future. The persistence of
ADHD past childhood/adolescence and its existence as
a condition in adulthood has only been recognised in
recent years and therefore continued surveillance using
data from databases such as THIN is required to
examine prescribing patterns further. Detailed infor-
mation on the ADHD diagnoses is not systematically
coded in the database and therefore it was not possible
to determine the severity of ADHD, which has been
demonstrated to predict persistence of ADHD from
childhood into adulthood [40]. In addition, this re-
search did not examine the presence of comorbid men-
tal health conditions and the influence that these may
have on the persistence of treatment. A follow-up
questionnaire study that examines some of the issues
behind treatment cessation and treatment persistence,
including comorbid conditions was conducted on a
sample of these patients and is reported separately.
Future work
In relation to persistence of prescribing of ADHD
pharmacological treatment, a number of areas should be
examined in the future, including the influence of psy-
chosocial and comorbid factors; the influence of stimu-
lant versus non-stimulant prescribing and the diagnostic
stability of ADHD over the period from childhood to
adulthood. While some of these data may be retrieved
from databases such as THIN, they may require supple-
mental data from questionnaires to GPs or psychiatrists.
Conclusion
Approximately 40% of patients who started pharma-
cological treatment for ADHD in childhood or ado-
lescence continued to receive prescriptions at age
18 years. Although persistence into adulthood, as
determined by GP prescribing, is higher than previ-
ously reported for the UK, figures are lower when
compared to rates of persistence of the condition in
adulthood. It is important that ongoing monitoringof GP prescribing patterns into later adulthood is
undertaken, in particular to observe the effects of
guideline recommendations such as those from NICE
and the British Association for Psychopharmacology.
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